Tasly Partners with VCBeat to Forge an Innovative Value Investment Model

2016Year5Month8Day, “2016“Tasly Scientific Research + Capital Summit Forum and Launch Ceremony of the R&D Cooperation and Innovation & Entrepreneurship Platform” Held in Tianjin. At the event, Tasly and VCBeat officially signed a cooperation agreement, under which both parties will engage in in-depth collaboration in the fields of healthcare investment and project incubation.

This collaboration marks Tasly’s formal entry into strategic positioning within the health industry, officially launching its new cross-sector partnership platform. VCBeat will also support Tasly in jointly creating a new model for innovative value investment, enabling capital and innovation to achieve mutual success amidst the prevailing policy and financial trends.

It is reported that VCBeat will leverage its strong research capabilities and project aggregation strengths in the field of healthcare innovation to jointly collect and mine data with Tasly.AWheel andAoutstanding projects in subsequent funding rounds, and participate in industry research, team communications, corporate due diligence, and other related activities as a partner.

Meanwhile, Tasly will also leverage its own full industrial chainIPDLeveraging its innovation-driven advantages and practical experience in pharmaceutical R&D, it provides precise incubation for early-stage projects in biomedicine and digital health. Meanwhile, it connects internal and external expert resources to uncover new drivers of innovative value, bridge the gap between R&D and capital, and establish interactive channels for products and projects.

Li Datao (left), founder of VCBeat, and Li Sirui (right), General Manager of the Strategic Development Department of Tasly Holding Group, signed the agreement on behalf of their respective parties.

At the press conference, Yan Kaijing, Executive Chairman of the Board of Directors of Tasly Holding Group, stated that to build a robust innovation and entrepreneurship platform, it is essential to first deepen engagement with universities, research institutions, and industry associations, integrate early-stage project databases, and comprehensively enhance project sourcing capabilities. Furthermore, by proactively analyzing industry development trends, new strategic growth spaces should be explored through top-level design, while leveraging investment maps for precise matching. On the “patient-centric” investment map, strategic investment partnerships should be identified to construct a comprehensive health ecosystem. In addition, it is necessary to establish multi-tiered pools of qualified experts across various specialized fields, and coordinate proprietary funds with collaborative funds to mitigate investment risks in early-stage projects.

“The golden age of investment in the broader health industry, driven by multiple factors, has arrived. Innovation must be integrated with capital support and new service mechanisms to unlock its value.” Yan Kaijing stated that Tasly, being consumer-centric, will establish a comprehensive health ecosystem integrating one-stop innovative health products and services. The company will closely align its investment strategy with six core industrial segments—biopharmaceuticals, traditional Chinese medicine (TCM), TCM raw materials, chemical pharmaceuticals, medical devices, and private healthcare—as well as two innovative fields: biotechnology and information technology.

Furthermore, Yan Kaijing showcased the innovative resources and needs of Tasly’s core sectors and domains, introduced the incubation system for innovative resources, and highlighted how the fund cluster business strengthens the integration capabilities within the industrial ecosystem.

As a key player in the partnership, VCBeat, China’s leading media outlet for internet healthcare venture capital and entrepreneurship, has been dedicated to innovation, entrepreneurship, and investment in the internet healthcare sector since its inception. Its four core business segments are media promotion, industry research, resource integration, and investment and financing facilitation. Today, VCBeat has become a leading voice platform in the field of internet healthcare and is widely recognized as the premier media source for internet healthcare venture capital and entrepreneurship. As an emerging technology media outlet and industry research institution, VCBeat exerts significant influence on venture capital activities and the industrial chain within the healthcare sector.

VCBeat operates VCBeat, VCBeat Research Institute, VCBeat Investment Division, the VCBeat WeChat Official Account, and the “Daifu” new media platform,VBSi Xiang Hui Salon, VCBeat Roadshow, and Star Healthcare Venture Capital CampO2OMultidimensional Service Units.

It is understood that Tasly Holding Group Co., Ltd. was established in1994The Group is a high-tech international enterprise group that takes the big health industry as its main thread, focuses on the biopharmaceutical industry, and integrates health services, medical rehabilitation, health preservation, and health management as its two wings. Since its establishment, the Group has consistently adhered to the corporate philosophy of “pursuing harmony between humanity and nature to improve quality of life” and the corporate vision of “creating health for all to share.” It remains committed to building the leading brand in the modernization and internationalization of traditional Chinese medicine, establishing itself as a premier brand in the big health industry, and continuously promoting the sustained and rapid development of the sector.

At this press conference, Yan Kaijing, Executive Chairman of the Board of Directors of Tasly Holding Group; Sun He, Vice President of Scientific Research at Tasly Holding Group; and Li Jing, Chairman of Pharmadex Jingwei;IMSShao Wenbin, Consulting Director, and Wei Jianzhong, Managing Partner at Jianqiao Fund Management, among other heavyweight figures from the biopharmaceutical and financial capital sectors, attended the report launch. The event was also attended by representatives from top-tier domestic and international institutions—including Yinying Ventures, Fuyu Asia, Lilly Asia Ventures, Qiming Venture Partners, Anlong Life Sciences Fund, Puhong Capital, JD Capital, Sinocare Pharma, Fortune Capital, Bencao Capital, and Morningside Venture Capital—as well as executives from leading pharmaceutical companies, prominent industry experts, and senior analysts. Distinguished guests also included delegates from authoritative Chinese research institutions such as the Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, and WuXi AppTec.